When AI designs a drug, who gets the credit?
Insilico claims its AI 'discovered' a drug. The biotech industry is racing ahead of a credit attribution framework that doesn't exist yet.
Why it matters
As AI moves from ideation to legitimate drug discovery, the biotech industry faces an emerging question: how do you assign intellectual property, authorship, and accountability when an AI system proposes the therapeutic candidate? This shapes hiring, patent law, and how biotech teams organize around AI.
The key facts
8 to knowInsilico Medicine claimed AI 'discovered' a pulmonary fibrosis drug candidate via generative models
Multiple biotech companies now using AI for rapid drug ideation
No established framework yet for credit/authorship in AI-assisted drug discovery
Issue touches IP law, team structure, and accountability in pharma
Insilico Medicine credits its generative AI platform with 'discovering' a pulmonary fibrosis drug candidate
Multiple biotech companies now use AI to rapidly generate drug ideas
Story touches IP, credit attribution, and role of human scientists in AI-accelerated drug discovery
Raises questions about job displacement and valuation of human expertise in biotech
Go to the source
MIT Technology Reviewtechnologyreview.com
Publisher excerpt: When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come…